Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.
Neuro Oncol. 2010 Dec;12(12):1269-77. doi: 10.1093/neuonc/noq095. Epub 2010 Aug 16.
BBR3610 is a polynuclear platinum compound, in which two platinums are linked by a spermine-like linker, and studies in a variety of cancers, including glioma, have shown that it is more potent than conventional platinums and works by different means. Identifying the mechanism of action of BBR3610 would help in developing the drug further for clinical use. Previous work showed that BBR3610 does not induce immediate apoptosis but results in an early G2/M arrest. Here, we report that BBR3610 induces early autophagy in glioma cells. Increased autophagy was also seen in intracranial xenografts treated with BBR3610. Interestingly, upon attenuation of autophagy by RNAi-mediated knockdown of ATG5 or ATG6/BECN1, no change in cell viability was observed, suggesting that the autophagy is neither an effective protection against BBR3610 nor an important part of the mechanism by which BBR3610 reduces glioma cell viability. This prompted a multimodal analysis of 4 cell lines over 2 weeks posttreatment with BBR3610, which showed that the G2/M arrest occurred early and apoptosis occurred later in all cell lines. The cells that survived entered a senescent state associated with mitotic catastrophe in 2 of the cell lines. Together, our data show that the response to treatment with a single agent is complex and changes over time.
BBR3610 是一种多核铂化合物,其中两个铂原子由 spermine 样连接物连接,在包括神经胶质瘤在内的多种癌症中的研究表明,它比传统的铂类药物更有效,并且作用方式不同。确定 BBR3610 的作用机制将有助于进一步将该药物开发用于临床应用。以前的工作表明,BBR3610 不会诱导立即凋亡,而是导致早期 G2/M 期阻滞。在这里,我们报告 BBR3610 诱导神经胶质瘤细胞早期自噬。用 BBR3610 处理颅内异种移植物也观察到自噬增加。有趣的是,通过 RNAi 介导的 ATG5 或 ATG6/BECN1 的敲低来抑制自噬,细胞活力没有变化,这表明自噬既不是 BBR3610 的有效保护,也不是 BBR3610 降低神经胶质瘤细胞活力的机制的重要组成部分。这促使我们对 BBR3610 处理后 2 周的 4 种细胞系进行了多模式分析,结果表明所有细胞系均早期出现 G2/M 期阻滞,随后出现凋亡。存活的细胞进入 2 种细胞系中与有丝分裂灾难相关的衰老状态。总之,我们的数据表明,单一药物治疗的反应是复杂的,并且随时间而变化。